Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria.
Br J Cancer. 2013 Apr 30;108(8):1677-83. doi: 10.1038/bjc.2013.135. Epub 2013 Apr 4.
Recent data indicate that tumour microenvironment, which is influenced by inflammatory cells, has a crucial role in cancer progression and clinical outcome of patients. In the present study, we investigated the prognostic relevance of preoperative neutrophil/lymphocyte (N/L) ratio on time to tumour recurrence (TTR) and overall survival (OS) in soft-tissue sarcoma (STS) patients who underwent curative surgical resection.
In all, 260 STS patients were included in this retrospective study. Kaplan-Meier curves and multivariate Cox proportional models were calculated for TTR and OS.
In univariate analysis, elevated N/L ratio was significantly associated with decreased TTR (hazard ratio (HR), 2.32; 95% confidence interval (CI), 1.30-4.14; P=0.005) and remained significant in the multivariate analysis (HR, 1.98; 95%CI, 1.05-3.71; P=0.035). Patients with elevated N/L ratio showed a median TTR of 77.9 months. In contrast, patients with low N/L ratio had a median TTR of 99.1 months. Regarding OS, elevated N/L ratio was also significantly associated with decreased survival in univariate analysis (HR, 2.90; 95%CI, 1.82-4.61; P=0.001) and remained significant in multivariate analysis (HR, 1.88; 95%CI, 1.14-3.12; P=0.014).
In conclusion, our findings suggest that an elevated preoperative N/L ratio predicts poor clinical outcome in STS patients and may serve as a cost-effective and broadly available independent prognostic biomarker.
最近的数据表明,受炎症细胞影响的肿瘤微环境在癌症进展和患者临床结局中起着关键作用。在本研究中,我们研究了术前中性粒细胞/淋巴细胞(N/L)比值与接受根治性手术切除的软组织肉瘤(STS)患者肿瘤复发时间(TTR)和总生存(OS)的相关性。
本回顾性研究共纳入 260 例 STS 患者。Kaplan-Meier 曲线和多变量 Cox 比例模型用于计算 TTR 和 OS。
单因素分析显示,升高的 N/L 比值与 TTR 降低显著相关(风险比(HR),2.32;95%置信区间(CI),1.30-4.14;P=0.005),且在多因素分析中仍具有显著意义(HR,1.98;95%CI,1.05-3.71;P=0.035)。N/L 比值升高的患者 TTR 中位数为 77.9 个月,而 N/L 比值低的患者 TTR 中位数为 99.1 个月。关于 OS,升高的 N/L 比值在单因素分析中也与生存率降低显著相关(HR,2.90;95%CI,1.82-4.61;P=0.001),在多因素分析中仍然显著(HR,1.88;95%CI,1.14-3.12;P=0.014)。
总之,我们的研究结果表明,术前升高的 N/L 比值预示着 STS 患者临床结局不良,可能成为一种具有成本效益且广泛可用的独立预后生物标志物。